SUNRISE, FL / ACCESSWIRE / March 30, 2017 / U.S. Stem Cell, Inc. (USCC) (OTCQB: USRM), a Florida corporation and leader in novel regenerative medicine solutions and physician-based stem cell therapies for human and animal patients, has developed a strategic alliance with Advanced Stem Cell Rx (ASC), a US based provider of regenerative medicine programs, including the development of autologous stem cell treatment centers throughout the US.

“Stem cells are critical to our survival and at the core of our regenerative and healing powers. They will play an immense role in redefining the preferred treatment method for the majority of diseases commonly afflicting mankind. We, at ASC, are proud to form a strong alliance with US Stem Cell Inc., one of the oldest and most respected stem cell research and therapy companies in the world,” stated Dr J.S. Landow, Managing Director of ASC.

ASC is commercializing many of the proprietary treatments developed by USSC and is currently implementing turnkey programs into qualified practices across the U.S. ASC has contracted with practices in over 20 states in the US. The company utilizes treatments which employ over 20 years of US Stem Cell’s international research findings and among the world’s elite cellular scientists and other luminaries in the stem cell field. Patient selection is critical, with acceptance for treatment based upon patient’s meeting specific criteria and undergoing a consultation with a member of the clinical team.

About U.S. Stem Cell, Inc.

US Stem Cell, Inc. (formerly Bioheart, Inc.) is an emerging enterprise in the regenerative medicine / cellular therapy industry. We are focused on the discovery, development, and commercialization of cell based therapeutics that prevent, treat, or cure disease by repairing and replacing damaged or aged tissue, cells, and organs, and restoring their normal function. We believe that regenerative medicine / cellular therapeutics will play a large role in positively changing the natural history of diseases, ultimately, we contend, lessening patient burdens, as well as reducing the associated economic impact disease imposes upon modern society.

Our business, which includes three operating divisions (US Stem Cell Training, Vetbiologics, and US Stem Cell Clinic), includes the development of proprietary cell therapy products, as well as revenue generating physician and patient based regenerative medicine / cell therapy training services, cell collection and cell storage services, the sale of cell collection and treatment kits for humans and animals, and the operation of a cell therapy clinic. Management maintains that revenues and their associated cash in-flows generated from our businesses will, over time, provide funds to support our clinical development activities, as they do today for our general business operations. We believe the combination of our own therapeutics pipeline combined with our revenue generating capabilities provides the Company with a unique opportunity for growth and a pathway to profitability.

Forward-Looking Statements:

Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may,” “will,” “to,” “plan,” “expect,” “believe,” “anticipate,” “intend,” “could,” “would,” “estimate,” or “continue,” or the negative other variations thereof, or comparable terminology, are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled “Risk Factors,” in its Annual Report on Form 10-K for the year ended December 31, 2016, and its Quarterly Reports on Form 10-Q.

Media Contact:

U.S. Stem Cell, Inc.
13794 NW 4th Street, Suite 212
Sunrise, Fl 33325
Phone: 954.835.1500
Email: usstemcell@us-stemcell.com

SOURCE: U.S. Stem Cell, Inc.

ReleaseID: 458577

NEW YORK, NY / ACCESSWIRE / March 30, 2017 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against SCYNEXIS, Inc. (“SCYNEXIS” or the “Company”) (NASDAQ: SCYX) and certain of its officers, and is on behalf of a class consisting of all persons or entities who purchased SCYNEXIS securities: (1) pursuant or traceable to SCYNEXIS’s initial public offering on or about May 2, 2014; and/or (2) from May 2, 2014 through March 2, 2017, inclusive (the “Class Period”). Such investors are advised to join this case by visiting the firm’s site: http://www.bgandg.com/scyx.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).

The complaint alleges that throughout the Class Period, Defendants made false and misleading statements and/or failed to disclose that (1) SCYNEXIS’ lead product, SCY-078, entailed substantial undisclosed health and safety risks; (2) as a result, SCYNEXIS had overstated the drug’s approval prospectus and/or commercial viability; and (3) consequently, SCYNEXIS’ public statements were materially false and misleading at all relevant times.

On March 2, 2017, after-market hours, Scynexis revealed that the U.S. Food and Drug Administration (“FDA”) has placed a clinical hold on clinical trials for the intravenous formulation of its lead product candidate, SCY-078, “until the FDA completes a review of all available pre-clinical and clinical data.” Scynexis encouraged investors that “[t]he clinical hold decision was issued by the FDA following a review of three mild-to-moderate thrombotic events in healthy volunteers receiving the IV formulation of SCY-078 at the highest doses and highest concentrations in a Phase 1 study.” Following this news, Scynexis stock dropped $0.57 per share, or over 17%, to close at $2.70 per share on March 3, 2017.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: http://www.bgandg.com/scyx, or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in SCYNEXIS, you have until May 8, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC

Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 457252

IRVINE, CA / ACCESSWIRE / March 30, 2017 / Khang & Khang LLP (the “Firm”) announces a class action lawsuit against FTD Companies, Inc. (“FTD” or the “Company”) (NASDAQ: FTD). Investors, who purchased or otherwise acquired shares between March 13, 2015 and March 14, 2017, inclusive (the “Class Period”), are encouraged to contact the Firm in advance of the May 19, 2017 lead plaintiff motion deadline.

If you purchased shares of FTD during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or via e-mail at joon@khanglaw.com.

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

According to the Complaint, FTD made false and/or misleading statements and/or failed to disclose that: FTD’s financial statements contained errors relating to the assessment of cross-border indirect taxes; that the Company lacked effective internal controls over financial reporting; that FTD overstated the benefits of the Provide acquisition; and that as a result of the above, FTD’s public statements were materially false and misleading at all relevant times.

On March 14, 2017, the Company announced that it identified “errors” relating to “the assessment of cross-border indirect taxes.” FTD added that, as a result of the errors, it would revise its previously-reported consolidated financial statements for the years ended December 31, 2015 and 2014 and for the quarters in the years ended December 31, 2015 and 2016.

If you wish to learn more about this lawsuit, or if you have questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or via e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

Contact:

Joon M. Khang, Esq.

Telephone: 949-419-3834

Facsimile: 949-225-4474

joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 458575

LOS ANGELES, CA / ACCESSWIRE / March 30, 2017 / Lundin Law PC , a shareholder rights firm, announces a class action lawsuit against JBS S.A. (“JBS” or the “Company”) (OTCQX: JBSAY) concerning possible violations of federal securities laws between June 2, 2015 and March 17, 2017, inclusive (the “Class Period”). Investors, who purchased or otherwise acquired shares during the Class Period, should contact the firm prior to the May 22, 2017 lead plaintiff motion deadline.

To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action yet. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

The Complaint alleges that throughout the Class Period, JBS made false and/or misleading statements and/or failed to disclose that its executives bribed regulators and politicians to subvert food inspections of its plants and overlook unsanitary practices, such as processing rotten meat and running plants with traces of salmonella.

On March 17, 2017, news outlets reported that Brazilian federal police raided the offices of JBS and dozens of other meatpackers following a two-year investigation into alleged bribery of regulators to subvert inspections of their plants and overlook unsanitary practices. Police arrested two JBS employees, among others. JBS stated in a securities filing that three of its plants and one of its employees were targeted in the probe.

When this information reached the public, shares of JBS declined in value, causing investors harm.

Lundin Law PC was established by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding the rights of shareholders.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact:

Lundin Law PC

Brian Lundin, Esq.

Telephone: 888-713-1033

Facsimile: 888-713-1125

brian@lundinlawpc.com
http://lundinlawpc.com/

SOURCE: Lundin Law PC

ReleaseID: 458574

NEW YORK, NY / ACCESSWIRE / March 30, 2017 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Babcock & Wilcox Enterprises, Inc. (“Babcock & Wilcox” or the “Company”) (NYSE: BW) and certain of its officers, and is on behalf of a class consisting of all persons or entities who purchased Babcock & Wilcox securities between July 1, 2015, and February 28, 2017, both dates inclusive (the “Class Period”). Investors are encouraged to learn more about this case by visiting the firm’s site: http://www.bgandg.com/bw.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).

The complaint alleges that throughout the class period, defendants made false and misleading statements and/or failed to disclose that: (1) Babcock & Wilcox’s Renewable business had productivity and scheduling issues; (2) these hidden problems decreased profit margins and worsened financial performance; (3) Babcock & Wilcox’s Renewable business suffered from problematic on-site project management and a lack of resources in engineering and project management groups, which resulted in overly aggressive project bidding, project delays, and engineering errors; (4) Babcock & Wilcox lacked adequate project management processes in its Renewable business, which negatively impacted performance on key projects from bidding through execution; (5) consequently, defendants’ statements about it outlook and expected financial performance were false and misleading and lack a reasonable basis when made.

On March 1, 2017, Babcock & Wilcox revealed its fourth quarter and full year 2016 financial results, which were below analyst projections, reporting “fourth quarter 2016 revenues of $380.0 million, a decrease of $122.7 million, or 24.4%, compared to the fourth quarter of 2015. GAAP earnings per share for the fourth quarter of 2016 were a loss of $1.47 compared to a loss per share of $0.10 for the fourth quarter of 2015.” Following this news, Babcock & Wilcox stock dropped over 39% during intraday trading on March 1, 2017.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: http://www.bgandg.com/bw, or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. You have until May 2, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC

Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 456940

NEW YORK, NY / ACCESSWIRE / March 30, 2017 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Desarrolladora Homex, S.A.B. de C.V. (“Homex” or the “Company”) (OTC PINK: DHHXF) (formerly NYSE: HXM; formerly OTCMKTS: DHOXQ; formerly OTCMKTS: DHOXY) and certain of its officers, on behalf of shareholders who purchased Homex American Depositary Shares between April 30, 2012 and May 5, 2016, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: http://www.bgandg.com/hxm.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements and failed to disclose that: (1) between 2010 and 2013, Homex overstated its revenue by 355%, or roughly $3.3 billion, by reporting fictitious sales of more than 100,000 homes; (2) between 2010 and 2013, Homex overstated the number of units it sold by over 100,000 units, or 317%, of actual units sold; (3) Homex and certain of its Headquarters Financial Reporting Personnel knowingly and intentionally engaged in a scheme to materially overstate Homex’s revenues, homes sold, and other related financial items; and (4) consequently, defendants’ statements about Homex’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable bases at all relevant times.

On March 3, 2017, Homex decided to resolve its charges with the U.S. Securities and Exchange Commission (“SEC”) for allegedly reporting $3.3 billion in deceitful sales revenue to boost its revenues in financial statements between 2010 and 2013. The SEC’s complaint alleges that during a three-year period, Homex exaggerated its revenue by 355%, or about $3.3 billion, by reporting fabricated sales of more than 100,000 homes, thereby four times inflating the numbers of homes actually sold. The SEC’s complaint also alleges that “Homex’s Headquarters Financial Reporting Personnel intentionally and knowingly uploaded false information into the Company’s internal reporting and accounting systems in order to perpetrate the fictitious revenue scheme.”

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: http://www.bgandg.com/hxm, or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Homex, you have until May 15, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC

Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 457268

NEW YORK, NY / ACCESSWIRE / March 30, 2017 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against HMS Holdings Corp. (“HMS” or the “Company”) (NASDAQ: HMSY) and certain of its officers, and is on behalf of a class consisting of all persons or entities who purchased HMS securities between May 10, 2016 through March 2, 2017, both dates inclusive (the “Class Period”). Such investors are advised to join this case by visiting the firm’s site: http://www.bgandg.com/hmsy.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).

The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, and failed to disclose that: (1) HMS lacked effective internal control over financial reporting; and (2) consequently, HMS’s financial statements were materially false and misleading at all relevant times.

On March 2, 2017, after market hours, HMS revealed that it would delay filing its annual report for the 2016 fiscal year, and that its auditor had identified what it believed was a material weakness in the Company’s internal controls over financial reporting related to CMS reserves. HMS also said that the it is “continuing to evaluate whether this issue affects its consolidated financial results, primarily focusing on prior periods in which revenue relating to the CMS business was recorded.” Following this news, HMS stock has dropped over 9% pre-market on March 3, 2017.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: http://www.bgandg.com/hmsy, or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in HMS, you have until May 2, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC

Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 456930

VANCOUVER, BC / ACCESSWIRE / March 30, 2017 / Nikos Explorations Ltd. (TSX-V: NIK) (OTC PINK: NKOSF) (“Nikos” or the “Company”) is pleased to announce that it has completed its previously announced drill program at the Borden Lake Extension Project near Chapleau, Ontario.

Drilling intersected similar rock types as those described by Probe Mines during their drilling at Borden Lake, including biotite gneiss, garnet biotite gneiss and pegmatite. Mafic metavolcanics rocks were also intersected and these may be part of the Borden Lake belt. The rocks are commonly altered with hematite, silica (both pervasive and as veinlets) and chlorite. Sulphide mineralization, primarily in the form of disseminated pyrite, and in some cases pyrrhotite, is identified in some of the altered zones.

A total of 1,662 metres of drilling was carried out in 13 holes to test chargeability anomalies identified by an induced polarization (IP) / resistivity survey located within 2.5 kilometres of Goldcorp’s Borden Lake Deposit. These anomalies occur up ice of high gold grain counts in till samples reported in 2016 (see News release dated March 29, 2016). A crew remains on site to complete logging and sampling of the core before sending the samples to an accredited laboratory for gold and multi-element assay.

“We are very pleased with the results of the drilling, especially given the presence of sulphide mineralization associated with altered zones in gneiss,” said Roger Moss, Chief Executive Officer of Nikos. “The intersection of the mafic metavolcanics rocks is also significant in the context of the regional geology. We look forward to receiving the results of the assays and planning future work on the property.”

Roger Moss, PhD., P.Geo., is the qualified person responsible for all technical information in this release.

About Borden Lake Extension:

The Borden Lake Extension Project covers an area of 55 square kilometres and lies approximately 5 km southeast of Goldcorp’s Borden Lake high grade gold zone where exploration has defined indicated resources of 0.56 MMoz grading 5.77g/t Au and inferred resources of 0.41 MMoz grading 5.49 g/tAu. This zone remains open along strike to the southeast. Exploration carried out by Nikos is the first known work on the property, which is located in the Kapuskasing Structural Zone. Nikos holds an option to earn a 100% interest in the property.

About Nikos Explorations:

Nikos Explorations is a Canadian based mineral exploration company focused on the acquisition and exploration of prospective gold projects in the Americas. The Company has 25,006,725 shares issued and outstanding and trades on the TSX Venture Exchange under the symbol NIK.

For more information, please contact:

Roger Moss, President and CEO
Tel: 416-704-8291

Or visit our website at: www.nikosexplorations.com.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

SOURCE: Nikos Explorations Ltd.

ReleaseID: 458573

NEW YORK, NY / ACCESSWIRE / March 30, 2017 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Adeptus Health Inc. (“Adeptus” or the “Company”) (NYSE: ADPT) and certain of its officers, and is on behalf of a class consisting of all persons or entities who purchased Adeptus securities April 29, 2016 through March 1, 2017, both dates inclusive (the “Class Period”). Investors are encouraged to learn more about this case by visiting the firm’s site: http://www.bgandg.com/adpt.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).

The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose that: (1) Adeptus had material weaknesses in its internal control over financial reporting in the areas of revenue recognition, accounts receivable, accounting for a contribution to an unconsolidated joint venture, and accounting for equity in (loss) earnings of unconsolidated joint ventures; and (2) consequently, defendants’ statements about Adeptus’ business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: http://www.bgandg.com/adpt, or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. You have until May 9, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC

Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 457256